Primary Biliary Cholangitis
Clinical Snapshot
Primary biliary cholangitis (PBC) — known before an international nomenclature change in 2015 as primary biliary cirrhosis, a name changed specifically because most patients are now diagnosed decades before cirrhosis ever develops — is a chronic, immune-mediated cholestatic liver disease. A T-cell-mediated autoimmune process progressively destroys the small and medium intrahepatic bile ducts, producing the histologic picture of nonsuppurative destructive cholangitis and, over years, ductopenia (bile duct loss). Loss of bile ducts impairs bile flow, and the resulting cholestasis drives progressive periportal fibrosis that can, if untreated or inadequately treated, eventually reach cirrhosis and its complications.[1]
PBC is overwhelmingly a disease of women — roughly 90-95% of patients are female — most often diagnosed between the ages of 40 and 60. It is genuinely uncommon under age 25.[1] The classic teaching presentation is fatigue and pruritus in a middle-aged woman, but this picture is now the exception rather than the rule: most patients today are identified earlier, from an isolated, otherwise-unexplained elevation in serum alkaline phosphatase (ALP) found incidentally on routine bloodwork, well before symptoms develop.[1]
Two biochemical features anchor essentially this entire chapter. The antimitochondrial antibody (AMA) is positive in roughly 90-95% of patients with PBC and is rarely found in anyone without it, making it close to a diagnostic marker in its own right when the clinical picture fits. Serum ALP is both the primary biochemical marker of cholestatic disease activity at diagnosis and — reassessed after 12 months of ursodeoxycholic acid (UDCA) therapy — the central yardstick used to decide whether a patient has responded adequately or needs second-line therapy added (see Assessment & Diagnosis and Choose Initial Treatment).[1][2]
Recognize the Condition
Symptomatic presentation
- Fatigue — the single most common symptom, reported by roughly half of patients at diagnosis; often disabling, does not correlate well with disease severity or biochemical response to treatment, and has no proven PBC-specific pharmacologic therapy (see Non-Pharmacologic Treatment).
- Pruritus — cholestatic itch affecting roughly 60-70% of patients at some point in the disease course, classically worse in the evening and at night, and involving the palms and soles as well as more generalized skin. It is a genuinely high-yield symptom to ask about directly, because patients frequently under-report it, assuming nothing can be done (see Treatment Targets and the dedicated pruritus algorithm and drug ladder later in this chapter).
- Right-upper-quadrant discomfort, dry eyes and dry mouth (sicca symptoms, from a frequently co-occurring Sjögren syndrome), and arthralgia.
Now more often asymptomatic at diagnosis
An increasing majority of patients are identified from an isolated ALP elevation on routine bloodwork, with no symptoms at all — a direct consequence of more frequent incidental liver-panel testing. This earlier detection is a genuinely good thing clinically (see Treatment Targets), but it means a normal-feeling, asymptomatic patient with an abnormal ALP should not be reassured out of a proper diagnostic work-up (see Assessment & Diagnosis).
Physical examination findings
| Finding | Mechanism / significance |
|---|---|
| Hepatomegaly | Common even in early, asymptomatic disease |
| Excoriations | From scratching due to often under-reported pruritus |
| Xanthelasma and xanthomas | From the hypercholesterolemia that commonly accompanies cholestasis (an abnormal lipoprotein-X particle, not conventional atherogenic LDL, drives much of this — see Special Populations for the cardiovascular-risk nuance) |
| Jaundice, scleral icterus | A marker of more advanced disease and hepatic synthetic compromise — not an early finding (see Red Flags & Refer) |
| Hyperpigmentation | Can develop with longstanding disease |
| Stigmata of cirrhosis (spider angiomata, palmar erythema, splenomegaly, caput medusae) | Only once cirrhosis has developed — see the Cirrhosis chapter for the full stigmata list and decompensation findings |
Associated autoimmune conditions
PBC clusters with other autoimmune disease more than most liver conditions do, and actively screening for these — rather than waiting for the patient to volunteer symptoms — is worthwhile: Sjögren syndrome (the most common association, in a substantial minority of patients — ask specifically about dry eyes/mouth), autoimmune thyroid disease (Hashimoto thyroiditis), systemic sclerosis/CREST syndrome, celiac disease, and rheumatoid arthritis.
Risk Factors
- Female sex — roughly 90-95% of patients are women; the reason for this striking sex skew is not fully understood, though X-chromosome and hormonal factors are implicated.[1]
- Age 40-60 at diagnosis — genuinely uncommon under age 25 and rare, though not absent, in men of any age.
- A first-degree relative with PBC — family clustering is well documented, including a markedly increased concordance in monozygotic twins compared with the general population, though routine genetic screening of asymptomatic relatives is not standard practice (unlike some other hereditary hepatology conditions) given the absence of a single causative gene.
- Another autoimmune condition — Sjögren syndrome, autoimmune thyroid disease, systemic sclerosis, celiac disease, or rheumatoid arthritis all co-occur with PBC more often than chance would predict (see Recognize the Condition).
- History of recurrent urinary tract infection — a longstanding epidemiologic association, hypothesized to reflect molecular mimicry between bacterial and human mitochondrial antigens, though causation is not established.
- Smoking history and certain HLA-DRB1 associations have both been linked to PBC risk in epidemiologic studies.
- Environmental/xenobiotic exposure (certain cosmetics, hair dye chemicals, and nail polish components) has been proposed as a contributing factor in genetically susceptible individuals, though the evidence is far less established than for the associations above.
Red Flags & Refer
Escalate beyond routine ambulatory PBC management for any of the following:
- Jaundice or a rising bilirubin — a marker of more advanced disease and declining hepatic synthetic function, not a routine or early finding; reassess disease severity and treatment response promptly rather than waiting for the next scheduled visit.
- Any sign of decompensated cirrhosis — new ascites, hematemesis/melena, hepatic encephalopathy, or new jaundice from synthetic failure — in a patient with PBC-related cirrhosis. Acute and longitudinal decompensation management (diuretic titration, variceal-bleed prophylaxis, lactulose/rifaximin, transplant-referral triggers) is covered in full in the separate Cirrhosis chapter and is not duplicated here; refer to that chapter's Red Flags & Refer and Treatment Failure / Next Step sections directly.
- Markedly elevated transaminases (AST/ALT above roughly 5× ULN) and/or a significantly elevated IgG, especially with interface hepatitis on biopsy — suspect AIH-PBC overlap syndrome rather than routine PBC; refer hepatology, since this variant typically needs added immunosuppression on top of UDCA (see Special Populations).
- Severe, refractory pruritus, particularly with sleep disruption, depression, or any suicidal ideation — cholestatic pruritus is a genuine, underrecognized driver of impaired quality of life and, in severe cases, suicidality; escalate the pruritus ladder promptly rather than reassuring the patient to "wait it out," and screen for depression directly (see the pruritus algorithm and Treatment Failure / Next Step).
- New or worsening liver signs in a patient on obeticholic acid — any new sign of hepatic decompensation warrants immediate discontinuation and urgent hepatology referral; do not rechallenge (see Choose Initial Treatment).
- A new liver mass, rapid unexplained clinical decline, or rising alpha-fetoprotein in a patient with PBC-related cirrhosis — evaluate for hepatocellular carcinoma; routine surveillance in cirrhotic PBC follows the same schedule as the Cirrhosis chapter (ultrasound ± AFP every 6 months, indefinitely).
Assessment & Diagnosis
The 2-of-3 diagnostic rule
PBC is diagnosed when a patient meets at least 2 of the following 3 criteria:[1]
- Biochemical evidence of cholestasis — an ALP elevation, generally at least 1.5× the upper limit of normal (ULN), without another identified cause.
- A positive antimitochondrial antibody (AMA) at a titer of 1:40 or greater — or, if AMA is negative, a PBC-specific antinuclear antibody pattern (anti-sp100 or anti-gp210) — present in the substantial majority of AMA-negative PBC cases and a useful serologic fallback.
- Histologic evidence of nonsuppurative destructive cholangitis and interlobular bile duct injury on liver biopsy.
In practice, most patients are diagnosed on serology alone: a positive AMA (≥1:40) combined with an ALP ≥1.5× ULN already satisfies 2 of the 3 criteria, and liver biopsy is not required to confirm the diagnosis in this classic scenario.[1]
When biopsy is genuinely needed
- AMA-negative disease with no PBC-specific ANA positivity, where histology becomes the second criterion needed to confirm the diagnosis.
- Suspected AIH-PBC overlap syndrome (disproportionately elevated transaminases and/or IgG) — biopsy helps confirm interface hepatitis and guide the decision to add immunosuppression.
- An atypical or discordant biochemical/serologic picture where an alternative or coexisting cause needs to be actively excluded.
Differential diagnosis and excluding other causes
Before finalizing a PBC diagnosis, reasonably exclude extrahepatic biliary obstruction with abdominal imaging (right-upper-quadrant ultrasound is typically sufficient), and consider primary sclerosing cholangitis, drug-induced cholestasis, and — much less commonly — hepatic sarcoidosis or a granulomatous cholangiopathy, particularly when AMA is negative and the clinical picture is otherwise atypical.
Baseline severity assessment
At diagnosis, obtain a complete liver panel (ALP, AST, ALT, total bilirubin, albumin, INR) to establish a baseline for the 12-month response assessment described in Choose Initial Treatment, and a non-invasive fibrosis assessment (transient elastography where available) to establish whether cirrhosis is already present — this materially affects which second-line agents are safe if UDCA response is inadequate later (see Choose Initial Treatment). A fasting lipid panel, thyroid function, and bone mineral density (DEXA) baseline are reasonable at diagnosis given the associations and monitoring needs covered in Monitoring & Follow-Up.
A monitoring point worth stating explicitly
AMA titer does not correlate with disease activity or treatment response and should not be repeated to "track" the disease once the diagnosis is established — ALP (and the other Paris-II parameters) is the marker that actually does this job (see Common Errors to Avoid).
Treatment Targets
- Achieve an adequate biochemical response to ursodeoxycholic acid by 12 months (Paris-II or an equivalent validated criterion), or promptly identify and treat an inadequate responder with second-line therapy.
- Prevent progression to cirrhosis and its complications; where cirrhosis is already established, transition to the longitudinal decompensation-prevention framework in the Cirrhosis chapter and maintain hepatocellular carcinoma surveillance.
- Control cholestatic pruritus — a genuinely high-yield, quality-of-life-driving symptom that should be actively asked about, not left for the patient to raise unprompted.
- Identify and, where feasible, address fatigue — while accepting that no PBC-specific pharmacotherapy reliably resolves it and that biochemical improvement does not guarantee symptomatic improvement.
- Prevent and treat the metabolic bone disease and fat-soluble vitamin deficiency that cholestatic malabsorption specifically drives.
- Recognize and appropriately manage AIH-PBC overlap syndrome rather than treating it as routine PBC.
- Screen for and manage associated autoimmune conditions (thyroid disease, Sjögren syndrome, celiac disease).
- Never discontinue effective ursodeoxycholic acid therapy once started, even after biochemical normalization — it is lifelong.
Choose Initial Treatment
First line, universal Ursodeoxycholic acid (UDCA / ursodiol), 13-15 mg/kg/day, is recommended for essentially every patient with PBC who has an abnormal liver enzyme value, regardless of histologic stage — this includes asymptomatic patients identified on incidental ALP elevation, not only those with symptoms.[1]
Round the calculated weight-based total to the nearest available capsule strength; UDCA is commonly given once daily with food for convenience, though dividing the total dose 2-3 times daily can improve gastrointestinal tolerability, particularly when starting therapy. Do not discontinue UDCA once started, even after biochemical response is achieved and sustained — biochemistry reliably relapses if UDCA is stopped, so it is a lifelong therapy, not a course with a natural endpoint.
Reassess ALP, AST, and total bilirubin no sooner than 6 months after starting UDCA — response can continue improving up to a year — with the formal response assessment made at 12 months.[1] The most widely used practical criteria are the Paris-II criteria: an adequate response is defined as ALP and AST both ≤1.5× ULN, with a normal total bilirubin, at 1 year of UDCA therapy. Patients meeting Paris-II have a long-term prognosis close to that of the general population; several other validated criteria (Barcelona, Rotterdam, Toronto) use closely similar thresholds and perform comparably.[2]
A complementary, more sophisticated tool is the GLOBE score, a continuous risk score calculated from age, bilirubin, ALP, albumin, and platelet count measured after 1 year of UDCA, that predicts long-term transplant-free survival rather than giving a simple responder/non-responder cutoff; the UK-PBC risk score serves a similar purpose. Neither is embedded as a calculator on this platform — both require lab values not entered elsewhere — but either is a reasonable way to communicate individualized long-term prognosis to a patient once 12-month labs are available.[3]
Predictors of a poorer UDCA response worth flagging early: younger age at diagnosis, male sex, and a higher baseline ALP or bilirubin. A patient with several of these features warrants closer-than-routine follow-up through the 12-month mark, since they are more likely to need second-line therapy added.
For a patient who does not meet Paris-II (or an equivalent criterion) at 12 months, or who cannot tolerate UDCA, add a second-line agent to ongoing UDCA (rather than substituting for it, except in the genuinely UDCA-intolerant patient). Three approved agents and one long-used off-label option are available; none has been compared head-to-head against another, so the choice is driven mainly by cirrhosis/decompensation status, pruritus burden, and cost/access — not by a preferred sequence.
Obeticholic acid — start 5 mg PO once daily; if the biochemical response remains inadequate after at least 3 months and the 5 mg dose is tolerated, increase to the maximum dose of 10 mg PO once daily. Contraindicated in PBC with decompensated cirrhosis, a prior hepatic decompensation event, or compensated cirrhosis with clinical or laboratory evidence of portal hypertension (e.g., varices, splenomegaly, thrombocytopenia) — a boxed warning added by the FDA in May 2021 after post-marketing surveillance identified serious liver injury progressing to hepatic decompensation or failure, some cases fatal or requiring transplantation, disproportionately in patients who already had cirrhosis at baseline.[4] Also carries a genuinely important counterpoint given how central pruritus control is to this chapter: obeticholic acid causes dose-dependent pruritus, and can worsen pre-existing pruritus — a real consideration when choosing among second-line agents for a patient whose pruritus is already a problem.
Elafibranor (dual PPAR-α/δ agonist) — 80 mg PO once daily, alone or added to UDCA, based on the ELATIVE trial.[5] Not recommended in decompensated cirrhosis; monitor cirrhotic patients for decompensation and consider discontinuing if the patient progresses to Child-Pugh B or C. Separate dosing from a bile acid sequestrant (cholestyramine, colesevelam) by at least 4 hours if both are used together for pruritus (see Common Errors to Avoid).
Seladelpar (selective PPAR-δ agonist) — 10 mg PO once daily, alone or added to UDCA, based on the RESPONSE trial.[6] Carries the same not-recommended-in-decompensated-cirrhosis caution as elafibranor. Notably, seladelpar reduced pruritus in its pivotal trial — a useful contrast with obeticholic acid when pruritus burden is a deciding factor between second-line agents.[6]
Bezafibrate — 400 mg PO once daily, added to UDCA. Not Health Canada-approved specifically for PBC, but a genuinely accessible Canadian off-label option: unlike obeticholic acid, elafibranor, and seladelpar, bezafibrate is an already-marketed, comparatively inexpensive lipid drug in Canada (it is not marketed at all in the United States), which matters for cost and access. In the placebo-controlled BEZURSO trial, 31% of patients on bezafibrate plus UDCA met Paris-II criteria at 24 months versus 0% on placebo plus UDCA.[7] Monitor creatinine (fibrate-associated elevation is a recognized signal) and for myalgia or drug-induced liver injury; use with caution or avoid in significant renal impairment, and safety data in patients with decompensated cirrhosis are limited, so the same cautious approach used for the other second-line agents is reasonable.[7]
Non-Pharmacologic Treatment
- Fatigue — before attributing fatigue to PBC itself, exclude other contributing causes (anemia, hypothyroidism, depression, poor sleep, an unrelated medical cause). No PBC-specific pharmacotherapy reliably resolves fatigue, and — a genuinely important expectation to set with patients — biochemical improvement on treatment does not reliably translate into less fatigue. Graded exercise and attention to sleep hygiene are reasonable, modestly helpful measures.
- Pruritus — non-pharmacologic measures alongside the drug ladder: lukewarm rather than hot showers/baths, fragrance-free emollients applied liberally, loose cotton clothing, keeping fingernails trimmed short to limit skin trauma from scratching, and avoiding known individual triggers.
- Sicca symptoms from co-occurring Sjögren syndrome — artificial tears and saliva substitutes as needed; refer ophthalmology/dentistry for persistent or severe symptoms.
- Bone health — weight-bearing exercise, smoking cessation, fall-risk reduction, and adequate dietary calcium/vitamin D intake, alongside the supplementation and monitoring covered in Pharmacologic Treatment Options and Monitoring & Follow-Up.
- Alcohol moderation and avoidance of unregulated herbal/dietary supplement products, which carry a disproportionate hepatotoxicity risk in an already cholestatic liver.
- Vaccination against hepatitis A and hepatitis B (if non-immune), and routine age-based adult immunizations — chronic liver disease is a reason to keep these current, not to defer them.
- Once cirrhosis is established: hepatocellular carcinoma surveillance (ultrasound ± AFP every 6 months, indefinitely) and the broader non-pharmacologic measures in the Cirrhosis chapter (sodium restriction if ascites develops, protein-adequate nutrition, shellfish-related infection-risk counseling) apply in full and are not repeated here.
Special Populations
Pregnancy
UDCA is generally continued through pregnancy — it is extensively used, at similar or higher doses, for intrahepatic cholestasis of pregnancy, and the accumulated safety experience supports continuing it in a pregnant patient with PBC rather than stopping it. Obeticholic acid, elafibranor, and seladelpar all have limited or no human pregnancy safety data and are generally avoided or held during pregnancy; individualize with hepatology and maternal-fetal medicine if a second-line agent is being considered around conception or during pregnancy. Pruritus can worsen in pregnancy; cholestyramine is considered compatible, while rifampin and naltrexone need individualized risk-benefit discussion with the treating team.
Men with PBC
PBC in men is less common (roughly 5-10% of cases) but is associated with a later average age at diagnosis, more advanced fibrosis at the time of diagnosis, and a generally less favorable prognosis than in women — a genuinely important point given how strongly the "typical patient" framing skews female. A lower threshold for closer monitoring, and for considering second-line therapy if the 12-month UDCA response is borderline, is reasonable in a man with PBC.
AIH-PBC overlap syndrome
A minority of patients have features of both PBC and autoimmune hepatitis (AIH) — disproportionately elevated transaminases (typically AST/ALT above roughly 5× ULN), a significantly elevated IgG, and interface hepatitis on biopsy, in addition to the standard PBC diagnostic criteria. This is a distinct clinical entity from straightforward PBC and typically needs immunosuppression added to UDCA — a corticosteroid, with or without azathioprine — directed by hepatology rather than managed as routine PBC.
Cardiovascular risk and hyperlipidemia
Hypercholesterolemia is common in PBC, driven largely by an abnormal cholesterol-carrying particle (lipoprotein-X) rather than conventional atherogenic LDL, and several observational studies have not shown the expected increase in cardiovascular events that the cholesterol level alone might suggest. This is worth knowing so an elevated lipid panel in a PBC patient is not automatically treated as identically high-risk as it would be in someone without cholestatic liver disease — use standard cardiovascular risk assessment and shared decision-making rather than reflexively escalating lipid-lowering therapy on the cholesterol number alone.
Older adults
No UDCA dose adjustment is specifically required for age. Bone-density monitoring and fracture-risk reduction (see Monitoring & Follow-Up) are especially important given baseline age-related osteoporosis risk stacking on top of cholestasis-related bone disease. Watch for polypharmacy interactions — rifampin is a potent inducer of multiple drug-metabolizing pathways, and cholestyramine binds and reduces the absorption of many concurrently taken oral medications (see Common Errors to Avoid).
Monitoring & Follow-Up
- ALP, AST, ALT, total bilirubin, and albumin periodically (commonly every 3-6 months) to track biochemical response and recalculate the Paris-II status or GLOBE/UK-PBC risk score at meaningful intervals.
- Do not repeat AMA titer to monitor disease activity — it does not track with disease severity or treatment response; ALP and the other Paris-II parameters are the correct tools for this.
- Non-invasive fibrosis assessment (elastography) periodically to detect progression toward cirrhosis, particularly in a patient with an inadequate UDCA response.
- Fat-soluble vitamin levels (A, D, E; INR/PT as a functional marker of vitamin K status) — particularly once jaundice or more advanced cholestasis develops, since impaired micellar bile-acid solubilization reduces fat-soluble vitamin absorption. A prolonged INR from vitamin K deficiency corrects with parenteral vitamin K, unlike a prolonged INR from true hepatic synthetic failure — a genuinely useful bedside distinction.
- Bone mineral density (DEXA) at baseline, repeated periodically (commonly every 2-3 years, more often if osteopenic or additional fracture-risk factors are present) — cholestasis-associated bone disease progresses gradually and silently until a fracture occurs.
- Thyroid function periodically, given the autoimmune thyroid disease association.
- Fasting lipid panel periodically, interpreted with the lipoprotein-X caveat in Special Populations rather than treated identically to a routine dyslipidemia case.
- On rifampin: baseline and periodic LFTs, and awareness of the (rare) hemolysis signal.
- On obeticholic acid: monitor closely for any sign of hepatic decompensation at every visit, particularly in a patient with any degree of fibrosis.
- Once cirrhosis develops: transition fully to the Cirrhosis chapter's longitudinal monitoring framework, plus hepatocellular carcinoma surveillance (ultrasound ± AFP every 6 months, indefinitely).
- Screen for depression and quality-of-life impact at follow-up, particularly in a patient with ongoing pruritus or fatigue.
Common Errors to Avoid
- Stopping UDCA once ALP normalizes, treating a good response as a "cure" rather than a lifelong therapy — biochemistry reliably relapses off treatment.
- Not re-checking that a patient's UDCA dose still matches their current weight, especially after significant weight change, before concluding the 12-month response is genuinely inadequate.
- Prescribing obeticholic acid without checking for decompensated cirrhosis, a prior decompensation event, or portal hypertension — the boxed-warning contraindication exists because this specific error has caused fatal or transplant-requiring liver injury.[4]
- Not asking directly about pruritus at follow-up — patients frequently under-report it, assuming nothing can be done, so proactive screening is necessary rather than waiting for it to be volunteered.
- Dosing cholestyramine (or another bile acid sequestrant) at the same time as UDCA or other oral medications rather than separating them by at least 2-4 hours, meaningfully reducing absorption of the co-administered drug.
- Repeating AMA titer to "monitor" disease activity or treatment response — it does not correlate with either; ALP and the Paris-II parameters are the correct tools.
- Missing bone-density and fat-soluble vitamin monitoring in a patient who looks and feels well on treatment — cholestasis-related bone disease and vitamin deficiency are both otherwise silent until a fracture or a functional deficiency manifests.
- Attributing every new or worsening symptom in a treated PBC patient reflexively to "just PBC" without considering AIH overlap, an unrelated cause of fatigue, disease progression, or a co-occurring autoimmune condition.
- Treating an elevated cholesterol in a PBC patient identically to a routine dyslipidemia case without accounting for the lipoprotein-X nuance (see Special Populations).
- Missing hepatocellular carcinoma surveillance once cirrhosis is established, particularly once a patient feels stable on second-line therapy.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Disease-modifying therapy — first-line, universal
Started in essentially every patient with an abnormal liver enzyme value at diagnosis, regardless of histologic stage, and continued lifelong.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ursodiol (ursodeoxycholic acid, UDCA) | Dosing: 13-15 mg/kg/day PO, lifelong | Diarrhea, weight gain; generally well tolerated at approved doses | None clinically significant at standard dosing | 13-15 mg/kg/day, once daily or divided for GI tolerability; round to the nearest available capsule strength. Never discontinue once started — biochemical response relapses off therapy. Formally reassess response at 12 months (Paris-II).[1] |
Disease-modifying therapy — second-line (add-on for an inadequate 12-month UDCA response, or monotherapy if UDCA-intolerant)
None of the four agents below has been directly compared against another; choice is driven by cirrhosis/decompensation status, pruritus burden, and cost/access.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Obeticholic acid | Starting dose: 5 mg PO once daily Titration: Increase to 10 mg once daily after >=3 months if tolerated and response inadequate Maximum: 10 mg PO once daily | Dose-dependent pruritus, can worsen pre-existing itch; fatigue, abdominal discomfort, arthralgia; boxed warning for hepatic decompensation/failure in cirrhosis | None clinically significant at standard dosing; separate from a bile acid sequestrant by several hours if co-administered | Contraindicated in decompensated cirrhosis, a prior decompensation event, or compensated cirrhosis with portal hypertension. Discontinue immediately and refer urgently for any sign of decompensation.[4] |
| Elafibranor | Dosing: 80 mg PO once daily | GI upset, musculoskeletal pain, headache | Separate dosing from cholestyramine/colesevelam by at least 4 hours | Dual PPAR-alpha/delta agonist. Not recommended in decompensated cirrhosis; monitor cirrhotic patients closely and consider discontinuing if progression to Child-Pugh B or C occurs.[5] |
| Seladelpar | Dosing: 10 mg PO once daily | GI upset, headache, abdominal distension | None clinically significant at standard dosing | Selective PPAR-delta agonist. Same not-recommended-in-decompensated-cirrhosis caution as elafibranor. Reduced pruritus in its pivotal trial — a useful choice when pruritus is already a problem, unlike obeticholic acid.[6] |
| Bezafibrate | Dosing: 400 mg PO once daily, added to UDCA | Myalgia, rising serum creatinine, rare drug-induced liver injury | Additive myopathy risk with statins; renally cleared — interacts with other renally-eliminated agents | Off-label in PBC (not Health Canada-approved for this indication) but genuinely accessible in Canada — marketed here as a lipid drug, unlike in the United States. Monitor creatinine; use with caution or avoid in significant renal impairment; safety data in decompensated cirrhosis are limited.[7] |
Cholestatic pruritus — stepwise ladder
Optimize disease-modifying therapy and non-pharmacologic measures first; step up sequentially, checking response and tolerability at each level before advancing.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cholestyramine | Starting dose: 4 g PO once daily Maximum: 16 g/day in divided doses | Constipation, bloating, GI upset; binds and reduces absorption of many co-administered oral drugs (including UDCA and thyroid hormone) | Reduces absorption of numerous oral medications taken at the same time — separate by several hours | First-line for cholestatic pruritus. Start 4 g/day, titrate up to 16 g/day in divided doses. Must be separated from UDCA and all other oral medications by at least 2-4 hours.[1] |
| Colesevelam | Dosing: Per product monograph, separated from other oral drugs by several hours | Constipation, GI upset — generally better tolerated than cholestyramine | Binds and reduces absorption of co-administered oral drugs, though somewhat less than cholestyramine | A reasonable alternative bile acid sequestrant when cholestyramine's palatability or tolerability is a barrier; less direct trial evidence specifically in PBC pruritus than cholestyramine. |
| Rifampin | Dosing: 150-300 mg PO twice daily | Idiosyncratic hepatotoxicity, rare hemolysis, orange discoloration of urine/tears/sweat, potent CYP3A4/drug-metabolizing enzyme induction | Numerous — potent inducer reduces levels of many concurrent drugs (e.g., warfarin, oral contraceptives, many immunosuppressants) | Second-line for pruritus refractory to a bile acid sequestrant. Check baseline and periodic LFTs — hepatotoxicity risk applies even though the drug is being used to treat a liver disease.[1] |
| Naltrexone | Starting dose: 12.5-25 mg/day Target dose: 50 mg/day, titrated over 1-2 weeks | Opioid-withdrawal-like reaction (abdominal cramping, gooseflesh, restlessness) if titrated too quickly; nausea; hepatotoxicity at supratherapeutic doses | Precipitates withdrawal in a patient on concurrent opioid therapy — confirm no opioid use before starting | Third-line for pruritus refractory to rifampin. Start low (12.5-25 mg/day) and titrate to 50 mg/day over 1-2 weeks. Check LFTs before starting — product labeling cautions against use in acute hepatitis/liver failure despite this established off-label indication in stable cholestatic disease.[1] |
| Sertraline | Dosing: 75-100 mg/day PO | GI upset, sexual dysfunction, standard SSRI class effects | Standard SSRI interaction profile (serotonergic drugs, some CYP interactions) | Fourth-line for pruritus refractory to naltrexone. A reasonable step before escalating to specialist-directed or investigational pruritus therapy.[1] |
Bone health and fat-soluble vitamin support
Cholestasis impairs micellar solubilization of fat-soluble vitamins and independently increases osteoporosis risk; supplementation is routine, not reserved for confirmed deficiency alone.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Calcium carbonate | Dosing: 1000-1500 mg elemental calcium/day, in divided doses with meals | GI upset, hypercalcemia with excessive intake | Reduces absorption of several oral drugs (e.g., some antibiotics, levothyroxine, bisphosphonates) if co-administered — separate dosing | Routine for essentially every patient with PBC.[1] |
| Vitamin D3 (cholecalciferol) | Dosing: 1000 IU/day | Hypercalcemia and hypervitaminosis D with excessive intake (uncommon at standard replacement doses) | None clinically significant at standard dosing | Routine alongside calcium; check levels periodically and treat confirmed deficiency with a repletion regimen per the product monograph. In advanced cholestasis, fat malabsorption may still limit oral fat-soluble vitamin absorption — water-soluble or parenteral formulations are used for confirmed deficiency unresponsive to standard oral dosing.[1] |
| Alendronate | Dosing: 70 mg PO once weekly | GI upset/esophagitis, rare osteonecrosis of the jaw or atypical femur fracture with long-term use | Reduced absorption with concurrent calcium, antacids, or other oral medications taken at the same time | First-line bisphosphonate once osteoporosis is confirmed on DEXA. Risedronate, zoledronic acid (IV, annual), or denosumab (subcutaneous, for bisphosphonate intolerance or significant renal impairment) are reasonable alternatives.[1] |
References
- Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases — American Association for the Study of Liver Diseases (Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M). Hepatology 2019;69(1):394-419
- Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis — Hepatology (Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R). Hepatology 2008;48(3):871-877
- Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy — Gastroenterology (Lammers WJ, Hirschfield GM, Corpechot C, et al., Global PBC Study Group). Gastroenterology 2015;149(7):1804-1812
- FDA Drug Safety Communication: FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis patients with advanced cirrhosis due to risk of serious liver injury — U.S. Food and Drug Administration. FDA Drug Safety Communication, May 2021
- Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis — New England Journal of Medicine (Kowdley KV, Bowlus CL, Levy C, et al., ELATIVE Study Investigators). N Engl J Med 2024;390(9):795-805
- A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis — New England Journal of Medicine (Hirschfield GM, Bowlus CL, Mayo MJ, et al.). N Engl J Med 2024;390(9):783-794
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis — New England Journal of Medicine (Corpechot C, Chazouillères O, Rousseau A, et al.). N Engl J Med 2018;378(23):2171-2181
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.